Dr. Sanders has served as a member of the Ultragenyx board since June 2021. Most recently, she served as executive vice president of development operations at Juno Therapeutics and strategic advisor to the office of the Celgene chief medical officer, following Celgene’s acquisition of Juno. She also served as transition advisor to the clinical development team at Bristol Myers Squibb (BMS), which acquired Celgene. Prior to her role at BMS, Dr. Sanders held numerous leadership positions over the course of 23 years at Genentech/Roche, including serving as senior vice president, global head of clinical operations and industry collaboration, for six years.
Dr. Sanders currently serves as a member of the board of directors of several biotechnology companies including Beigene Ltd., Molecular Templates Inc., Legend Biotech Corporation and AltruBio Inc. (formerly AbGenomics Inc.). Dr. Sanders is an advisory committee member for the George Schultz Innovation Fund of the University of Chicago. She is also co-chair of the board of advisors and chair of the science and technology advisory committee for the Fred Hutchinson Cancer Research Center. Dr. Sanders graduated magna cum laude from the University of the Philippines where she earned a B.S. and M.S. in statistics. She also earned an M.A. and Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania.